Product logins

Find logins to all Clarivate products below.


Regina Galera

Director, Regulatory and Clinical Consulting, Life Sciences and Healthcare

Regina is a MSc Industrial Pharmacist by the University of Barcelona with over 19 years of experience in the Pharmaceutical and Medical Device Industry. She is a seasoned professional within the Regulatory, Clinical, Quality and Vigilance fields across EMEA, North America, Latin America, Asia Pacific and Japanese markets.

She has experience both in Industry with international companies such as Alcon (Novartis), Smith & Nephew and Olympus as well as in Consulting (IQVIA) interacting with Competent Authorities, Notified Bodies, Certification Bodies and Third-party auditors. Among others, she has worked with ophthalmic drugs, antibiotics, anesthetics, aesthetic products, combination products, class I-III medical devices, including implantable, custom-made, active and software as a medical device (SaMD).

She leads a team of experienced consultants who are focused on developing strategic technology enabled customized Regulatory and Clinical solutions with a holistic approach for Pharmaceuticals, Biologics, Medical Devices, Combination products and Consumer Health covering more than 140 countries.


arrow_forward
Get in touch with Regina

Latest news

News July 10, 2026
Clarivate to Report Second Quarter 2026 Results on July 29, 2026

London, U.K., July 10, 2026 – (PR Newswire) – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the second…

News July 9, 2026
Clarivate Releases G20 Research and Innovation Scorecard 2026

Tracking global research power, impact and collaboration as G20 priorities shift

News July 6, 2026
Clarivate Announces Sale of Life Sciences & Healthcare Segment for $600 Million

Transaction sharpens company’s focus on AI-driven transformative intelligence for its leading Academia & Government and Intellectual Property segments Enhances financial profile by improving revenue mix, expanding Adjusted EBITDA margin and…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.